Last week Cellular Dynamics International (CDI) and Life Technologies announced a partnership to commercialize a set of three novel products that are optimized to consistently develop and grow human induced pluripotent stem (iPS) cells for both research and bioproduction purposes. This partnership combines CDI’s leadership in human iPS cell development and manufacturing as well as Life Technologies’ expertise in the commercialization of stem cell research tools
By creating a consistent, defined reagent system, these products overcome the limitations associated with commonly-used stem cell culture products, such as bovine serum albumin (BSA) and lipids, by reducing the variability in results inherent with other reagents. Generating consistent performance supports the advancement of translational stem cell research and drug discovery efforts. These products also further research efforts by enabling large-scale production of human iPS cells to be conducted.
Recent studies published in Nature Methods and PLoS One validated the effectiveness of CDI’s products, and presentations by customers of studies using the company’s human iPS cells at the Society of Toxicology (SOT) Annual Meeting demonstrated the superiority of CDI’s products compared to other cell models.
In addition, CDI was named last year’s overall Gold winner in The Wall Street Journal Technology Innovation Awards based on the ability of its iPS cell manufacturing technology to facilitate understanding of human biology, improve the drug discovery process and develop cell-based therapies to treat human diseases.
Read more about The Wall Street Journal Technology Innovation Awards in the following article:
